AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29337861 — intervention group
Group type: COMPARATOR
Intervention: Animal protein meal (eggs without fiber supplementation)
Number of subjects: 35
Study 26996984 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) intervention
Number of subjects: 18
Study 26996984 — intervention group
Group type: COMPARATOR
Intervention: Usual adherence education and side‐effect management (Control)
Number of subjects: 18
Study 24655114 — intervention group
Group type: EXPERIMENTAL
Intervention: intra‐oesophageal infusion of acidic solution (0·1 N HCl; pH 1·2)
Number of subjects: 15
Study 24655114 — intervention group
Group type: COMPARATOR
Intervention: intra‐oesophageal saline infusion
Number of subjects: 15
Study 24655114 — intervention group
Group type: COMPARATOR
Intervention: no infusion
Number of subjects: 15
Study 24655114 — intervention group
Group type: EXPERIMENTAL
Intervention: oesophageal acid stimulation
Number of subjects: 15
Study 24655114 — intervention group
Group type: EXPERIMENTAL
Intervention: oesophageal acid infusion
Number of subjects: 15
Study 22525653 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylsulfonylmethane (MSM) supplementation (50 mg/kg in 200 mL water)
Number of subjects: 18
Study 22525653 — intervention group
Group type: COMPARATOR
Intervention: Placebo (200 mL water)
Number of subjects: 18
Study 19939872 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 26828 at 3 and 6 μg/kg
Number of subjects: 0
Study 19939872 — intervention group
Group type: COMPARATOR
Intervention: Midazolam intravenous 0.1 mg/kg
Number of subjects: 0
Study 19939872 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 26828 at doses higher than 1 μg/kg
Number of subjects: 0
Study 19939872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19939872 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 26828 at doses up to 0.3 μg/kg
Number of subjects: 0
Study 19939872 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 26828 at higher doses
Number of subjects: 0
Study 18369631 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiographs evaluated by radiologists
Number of subjects: 277
Study 18369631 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribronchial cuffing in supine position
Number of subjects: 277
Study 18369631 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular pedicle width in supine position
Number of subjects: 277
Study 18369631 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of radiographic features
Number of subjects: 277
Study 18369631 — intervention group
Group type: COMPARATOR
Intervention: BNP testing
Number of subjects: 277
Study 15897952 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolization leading to occlusion of blood vessels
Number of subjects: 0
Study 15897952 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization leading to reopening of blood vessels
Number of subjects: 0
Study 12522402 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic injection of bupivacaine with adrenaline
Number of subjects: 40
Study 12522402 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 40
Study 10643842 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab (monoclonal antibody to the F protein of RSV)
Number of subjects: 0
Study 10643842 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA (enzyme-linked immunosorbent assay)
Number of subjects: 0
Study 10643842 — intervention group
Group type: COMPARATOR
Intervention: Plaque assay
Number of subjects: 0
Study 10643842 — intervention group
Group type: COMPARATOR
Intervention: Inflammatory indices (white blood cell count, myeloperoxidase, eosinophilic cationic protein)
Number of subjects: 0
Study 8851829 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 10 mg/kg/h propofol and 40% O2/air (n = 14)
Number of subjects: 35
Study 8851829 — intervention group
Group type: COMPARATOR
Intervention: Group B: 1-0.7% isoflurane and 40% N2O/O2 (n = 10)
Number of subjects: 35
Study 8851829 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline prolactin levels for Group A
Number of subjects: 35
Study 8851829 — intervention group
Group type: COMPARATOR
Intervention: Baseline prolactin levels for Group B
Number of subjects: 35
Study 8851829 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative prolactin levels for Group A
Number of subjects: 35
Study 8851829 — intervention group
Group type: COMPARATOR
Intervention: Postoperative prolactin levels for Group B
Number of subjects: 35
Study 7524774 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic approach
Number of subjects: 24
Study 7524774 — intervention group
Group type: COMPARATOR
Intervention: Open supraclavicular approach
Number of subjects: 24
Study 3365916 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg diflunisal
Number of subjects: 161
Study 3365916 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg codeine
Number of subjects: 161
Study 3365916 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg diflunisal plus 60 mg codeine
Number of subjects: 161
Study 3365916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 29764464 — intervention group
Group type: EXPERIMENTAL
Intervention: DayTime (DT) casein supplementation
Number of subjects: 13
Study 29764464 — intervention group
Group type: EXPERIMENTAL
Intervention: NightTime (NT) casein supplementation
Number of subjects: 13
Study 28446141 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast Cancer e‐Support program (mobile application) plus routine care
Number of subjects: 108
Study 28446141 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 108
Study 27268415 — intervention group
Group type: EXPERIMENTAL
Intervention: VIPP-Twins intervention (five biweekly sessions, home visits, videotaped interactions, positive feedback)
Number of subjects: 225
Study 27268415 — intervention group
Group type: EXPERIMENTAL
Intervention: VIPP-Twins intervention
Number of subjects: 225
Study 23406256 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive anti-inflammatory agents (intravitreal and sub-Tenon's triamcinolone, oral flurbiprofen, and guttae prednisolone 1.0%)
Number of subjects: 0
Study 23406256 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 21211651 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fluticasone
Number of subjects: 0
Study 21211651 — intervention group
Group type: COMPARATOR
Intervention: Montelukast
Number of subjects: 0
Study 19948624 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent mentors (PMs) intervention
Number of subjects: 220
Study 19948624 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent mentors (PMs) intervention (high participants)
Number of subjects: 220
Study 19948624 — intervention group
Group type: COMPARATOR
Intervention: Traditional asthma care (control group)
Number of subjects: 220
Study 17845685 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone-based regimens (primary proton pump inhibitor-based)
Number of subjects: 0
Study 17845685 — intervention group
Group type: COMPARATOR
Intervention: Furazolidone-based regimens
Number of subjects: 0
Study 17845685 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine bismuth citrate + furazolidone-based triple regimens
Number of subjects: 0
Study 17845685 — intervention group
Group type: EXPERIMENTAL
Intervention: H(2) antagonist + furazolidone + one other antibiotic
Number of subjects: 0
Study 17845685 — intervention group
Group type: COMPARATOR
Intervention: Bismuth-based triple therapies
Number of subjects: 0
Study 17845685 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary quadruple regimens containing furazolidone
Number of subjects: 0
Study 17845685 — intervention group
Group type: COMPARATOR
Intervention: Second-line schedules containing furazolidone
Number of subjects: 0
Study 17845685 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-line 'rescue' therapies
Number of subjects: 0
Study 15485440 — intervention group
Group type: EXPERIMENTAL
Intervention: NavX-guided ablation (group II, 20 patients)
Number of subjects: 40
Study 11524192 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia plus intracameral lidocaine 1%
Number of subjects: 60
Study 11524192 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar anesthesia
Number of subjects: 60
Study 9773784 — intervention group
Group type: EXPERIMENTAL
Intervention: Uremic patients
Number of subjects: 29
Study 9773784 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 29
Study 8568016 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicoderm (nicotine transdermal system), 21 mg/day applied for 24 hours
Number of subjects: 14
Study 8568016 — intervention group
Group type: COMPARATOR
Intervention: Controlled smoking (30 cigarettes at half‐hourly intervals on days 1 and 5; ad libitum smoking on days 2‐4)
Number of subjects: 14
Study 2754147 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic-treated group (maternal avoidance of cow's milk, egg, and peanut; infant use of casein hydrolysate; avoidance of solid foods for 6 months; cow's milk, corn, soy, citrus, and wheat for 12 months; egg, peanut, and fish for 24 months)
Number of subjects: 288
Study 2754147 — intervention group
Group type: COMPARATOR
Intervention: Control group (unrestricted maternal diet; infants followed American Academy of Pediatrics feeding guidelines)
Number of subjects: 288
Study 2754147 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic-treated group
Number of subjects: 288
Study 2754147 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 288
Study 14861 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 30
Study 14861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30587323 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenke 1AR curves (n = 43)
Number of subjects: 94
Study 30587323 — intervention group
Group type: COMPARATOR
Intervention: Lenke 1AL curves (n = 51)
Number of subjects: 94
Study 28633671 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg/day
Number of subjects: 40
Study 28633671 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 40
Study 26251066 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzylpenicillin
Number of subjects: 350
Study 26251066 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin combined with sulbactam
Number of subjects: 350
Study 26251066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 350
Study 26251066 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 350
Study 24001747 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50-μg/d)
Number of subjects: 107
Study 24001747 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2 (50-μg/d)
Number of subjects: 107
Study 24001747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 21933429 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based worksite weight loss program
Number of subjects: 19
Study 21933429 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher income households, higher education levels, and health literacy proficiency
Number of subjects: 19
Study 18624932 — intervention group
Group type: EXPERIMENTAL
Intervention: Population studies
Number of subjects: 45
Study 18624932 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based studies
Number of subjects: 45
Study 16683130 — intervention group
Group type: EXPERIMENTAL
Intervention: THA through superior capsulotomy exposure (study group)
Number of subjects: 213
Study 16683130 — intervention group
Group type: COMPARATOR
Intervention: THA through direct lateral exposure (control group)
Number of subjects: 213
Study 12954158 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg daily for 12 months)
Number of subjects: 44
Study 12954158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 10963459 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ascorbate treatment; specific dosage and duration not mentioned.
Number of subjects: 0
Study 10963459 — intervention group
Group type: COMPARATOR
Intervention: Oral ascorbate treatment; specific dosage and duration not mentioned.
Number of subjects: 0
Study 2160516 — intervention group
Group type: EXPERIMENTAL
Intervention: 10^4 PFU dose of rhesus rotavirus vaccine
Number of subjects: 320
Study 2160516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 2160516 — intervention group
Group type: EXPERIMENTAL
Intervention: 10^3 PFU dose of rhesus rotavirus vaccine
Number of subjects: 320
Study 10246464 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency-contracting approach
Number of subjects: 91
Study 10246464 — intervention group
Group type: COMPARATOR
Intervention: Educational approach
Number of subjects: 91
Study 10246464 — intervention group
Group type: COMPARATOR
Intervention: Routine-care approach
Number of subjects: 91
Study 30346660 — intervention group
Group type: EXPERIMENTAL
Intervention: Mercaptopurine 50 mg single oral dose
Number of subjects: 48
Study 30346660 — intervention group
Group type: EXPERIMENTAL
Intervention: Mercaptopurine pharmacokinetics
Number of subjects: 48
Study 28886083 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led telephone-based intervention
Number of subjects: 768
Study 26947731 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary fibular allograft (IFA) with locking compression plates (LCPs)
Number of subjects: 60
Study 26947731 — intervention group
Group type: COMPARATOR
Intervention: Shoulder hemi-arthroplasty (HA)
Number of subjects: 60
Study 24552372 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine supplementation (7 g leucine, 93 kcal, 14.5 g whey-based protein)
Number of subjects: 18
Study 24552372 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric isonitrogenous control (0.3 g LEU, 93 kcal, 11.3 g collagen protein)
Number of subjects: 18
Study 22119991 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat, high fiber (LFHF) diet
Number of subjects: 51
Study 22119991 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified National Cancer Institute diet supplemented with a soy-based beverage and encapsulated fruit and vegetable juice concentrates (FVJC)
Number of subjects: 51
Study 20580002 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese version of the Schizotypal Personality Questionnaire‐Brief
Number of subjects: 618
Study 20580002 — intervention group
Group type: COMPARATOR
Intervention: Control group (scores <15)
Number of subjects: 618
Study 17395894 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilayer-release methylphenidate (qd)
Number of subjects: 14
Study 17395894 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release methylphenidate (bid)
Number of subjects: 14
Study 16311436 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chondroitin sulfate treatment
Number of subjects: 161
Study 16311436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 12170105 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tryptophan depletion (concentrated amino acid drink that resulted in a rapid and significant decline in plasma free tryptophan)
Number of subjects: 12
Study 12170105 — intervention group
Group type: COMPARATOR
Intervention: Placebo depletion (similar drink containing tryptophan)
Number of subjects: 12
Study 10502583 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ofloxacin
Number of subjects: 31
Study 10502583 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ofloxacin
Number of subjects: 31
Study 10502583 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of ofloxacin
Number of subjects: 31
Study 7490920 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion therapy (thrombolytic agents or immediate angioplasty)
Number of subjects: 0
Study 7490920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancillary treatments to reduce reperfusion injury
Number of subjects: 0
Study 7490920 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer agents (hirudin, glycoprotein IIb-IIIa receptor inhibitors)
Number of subjects: 0
Study 2614709 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupillary light occluder
Number of subjects: 291
Study 2614709 — intervention group
Group type: COMPARATOR
Intervention: No pupillary light occluder
Number of subjects: 291
Study 6460591 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuva‐Seal
Number of subjects: 200
Study 6460591 — intervention group
Group type: EXPERIMENTAL
Intervention: Delton
Number of subjects: 200
Study 30948907 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic hepatectomy
Number of subjects: 0
Study 30948907 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 27993418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Ketorolac 10 mg
Number of subjects: 240
Study 27993418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Ketorolac 15 mg
Number of subjects: 240
Study 27993418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Ketorolac 30 mg
Number of subjects: 240
Study 27993418 — intervention group
Group type: COMPARATOR
Intervention: Rescue analgesic (Intravenous morphine 0.1 mg/kg)
Number of subjects: 240
Study 27993418 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects (dizziness, nausea, headache)
Number of subjects: 240
Study 27012258 — intervention group
Group type: EXPERIMENTAL
Intervention: Familias Unidas intervention
Number of subjects: 367
Study 24288238 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine monotherapy (up to 80 mg or maximum tolerated dosage for 12 weeks)
Number of subjects: 138
Study 24288238 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatments with add-on strategies: placebo, clomipramine, or quetiapine (for an additional 12 weeks)
Number of subjects: 138
Study 23192994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerclage
Number of subjects: 986
Study 23192994 — intervention group
Group type: COMPARATOR
Intervention: No cerclage
Number of subjects: 986
Study 19956961 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg twice daily) and CC
Number of subjects: 43
Study 19956961 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic ovarian drilling (LOD) and CC
Number of subjects: 43
Study 18329818 — intervention group
Group type: COMPARATOR
Intervention: Placebo (A)
Number of subjects: 10
Study 18329818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (B)
Number of subjects: 10
Study 18329818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin and GHRH (C)
Number of subjects: 10
Study 18329818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin and CRH (D)
Number of subjects: 10
Study 15983181 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity PRT (80% maximum load)
Number of subjects: 60
Study 15983181 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity PRT (20% maximum load)
Number of subjects: 60
Study 15983181 — intervention group
Group type: COMPARATOR
Intervention: GP care
Number of subjects: 60
Study 12027979 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop ileostomy
Number of subjects: 80
Study 12027979 — intervention group
Group type: COMPARATOR
Intervention: Loop transverse colostomy
Number of subjects: 80
Study 10625099 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% metronidazole dental gel applied once a week for two weeks
Number of subjects: 8
Study 10625099 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing
Number of subjects: 8
Study 7738616 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesna
Number of subjects: 147
Study 7738616 — intervention group
Group type: COMPARATOR
Intervention: Forced diuresis
Number of subjects: 147
Study 7738616 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent BK viruria
Number of subjects: 147
Study 7738616 — intervention group
Group type: EXPERIMENTAL
Intervention: Single urine sample positive for BK virus
Number of subjects: 147
Study 7738616 — intervention group
Group type: EXPERIMENTAL
Intervention: No BK virus excretion
Number of subjects: 147
Study 1697373 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 37
Study 1697373 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 37
Study 1697373 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 37
Study 1697373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 6407539 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 12
Study 6407539 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 12
Study 30022269 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoMTA Plus
Number of subjects: 54
Study 30022269 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 54
Study 30022269 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA Angelus
Number of subjects: 54
Study 30022269 — intervention group
Group type: COMPARATOR
Intervention: Negative Control
Number of subjects: 54
Study 28420726 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver reproducibility assessment with 1% cut point
Number of subjects: 120
Study 28420726 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver reproducibility assessment with 50% cut point
Number of subjects: 120
Study 28420726 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver reproducibility assessment with 1% cut point
Number of subjects: 120
Study 28420726 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver reproducibility assessment with 50% cut point
Number of subjects: 120
Study 26426736 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 0
Study 26426736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25022108 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 54
Study 25022108 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 54
Study 22949599 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS)
Number of subjects: 90
Study 20058615 — intervention group
Group type: EXPERIMENTAL
Intervention: Topneuter (Teerjin)
Number of subjects: 52
Study 20058615 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim (Huierxue)
Number of subjects: 52
Study 17584555 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg, 3 times a day)
Number of subjects: 10